Login / Signup

[Treatment of secondary glaucoma following intravitreal anti-VEGF therapy with the XEN® gel stent and mitomycin C].

Mohammad Seleman BedarUlrich Kellner
Published in: Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft (2020)
The XEN® gel stent in combination with mitomycin C is a therapeutic option for difficult to adjust secondary glaucoma following intravitreal anti-VEGF therapy. A continuation of intravitreal anti-VEGF therapy did not lead to a recurrent increase of intraocular pressure.
Keyphrases
  • vascular endothelial growth factor
  • endothelial cells
  • diabetic retinopathy
  • age related macular degeneration
  • mesenchymal stem cells
  • optic nerve
  • cell therapy